查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012692

自体免疫疾病诊断市场：2026-2032年全球市场预测（按产品类型、检测类型、技术、检体类型、适应症、分销管道和最终用户划分）

Autoimmune Disease Diagnostics Market by Product, Test Type, Technology, Sample Type, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自体免疫疾病诊断市场价值将达到 62.3 亿美元，到 2026 年将成长至 66.8 亿美元，复合年增长率为 7.45%，到 2032 年将达到 103 亿美元。

主要市场统计数据
基准年 2025 62.3亿美元
预计年份：2026年 66.8亿美元
预测年份 2032 103亿美元
复合年增长率 (%) 7.45%

概述自体免疫疾病诊断市场，涵盖临床复杂性、技术进步以及相关人员面临的策略挑战。

自体免疫诊断领域正处于一个转折点，其驱动力来自临床需求的融合、分析技术的进步以及对更早期、更精准疾病检测日益增长的重视。临床医师需要能够确认自体免疫活动、对疾病表型进行分层、预测疾病进展并辅助个人化治疗方法选择的检测方法和平台。同时，检查室管理者和医疗系统负责人也在努力平衡营运效率与高通量、多重检测能力以及与电子健康记录和临床决策支援工具整合的资料输出需求。

快速的技术融合、数据驱动的诊断、不断发展的护理路径以及不断变化的支付方趋势，正在全面重新定义自体免疫疾病的检测和管理。

重塑自体免疫疾病诊断的变革性变化反映了技术创新、数据驱动的临床工作流程以及不断发展的医疗服务模式的交汇融合。首先，分子诊断和多重检测平台的成熟提高了诊断的精细度，使得同时检测多种自体抗体、发炎标记或基因层面特征成为可能。这种能力正在改变传统的逐步检测流程，缩短检测週期，减少连续检测的需求，进而影响检查室的检测能力和试剂需求。

评估 2025 年美国关税政策变更对供应链、医疗设备采购、临床实验室工作流程和产业获利能力的累积影响。

2025年美国关税政策和贸易趋势的变化，将为本已复杂的诊断生态系统带来更多挑战，其影响波及零件采购、检查室营运和采购决策等各个面向。依赖跨境供应链获取关键试剂、检测组件或仪器子系统的製造商，可能面临更高的接收成本和更长的前置作业时间，迫使他们重新评估供应商关係和库存策略。

基于细分的详细洞察：将测试类型、技术、检体类型、适应症、分销管道和最终用户的细分转化为可操作的策略指南。

基于细分市场的观点阐明了诊断技术的创新和普及如何与临床需求和实际操作相交织。试剂盒/试剂和仪器之间的产品级区别是采购决策的核心。检查室倾向于选择可跨平台柔软性的开放式试剂，而集中式机构则倾向于投资能够实现高通量检测和自动化的仪器。检测类型的多样性凸显了多种临床路径。自体抗体和免疫学检测、基因检测、影像检查和发炎标记检测各自发挥不同的诊断作用。在自体抗体和免疫学检测中，抗核抗体、环瓜氨酸肽抗体和疾病特异性自体抗体等标准检测组合仍然是许多诊断的基础。同时，基因检测已扩展到染色体和分子水​​平，并越来越多地用于疾病的最终诊断和风险分层。磁振造影（MRI）、PET/CT和超音波等影像技术不断补充结构和功能讯息，而 C 反应蛋白和红血球沉积速率等发炎标记物则提供了对疾病活动的快速和广泛了解。

影响美洲、欧洲、中东和非洲以及亚太地区诊断方法采用的区域趋势及其对商业化和临床合作的影响。

区域趋势显着影响诊断技术应用的速度和形式、监管方式以及商业策略。在美洲，临床网路和中心检查室是高通量平台和综合血清学检测组合的关键驱动力。同时，证据的收集和与保险公司的谈判往往受到重视，进而影响报销策略。在该地区，将诊断技术创新与临床流程重新设计相结合的检查室-临床一体化模式通常发挥着主导作用，并且在当地临床领导者的支持和卫生经济数据的帮助下，可以加速技术的应用。

诊断试剂製造商、试剂供应商、仪器供应商和服务供应商之间的竞争与合作动态塑造了创新流程和上市时间策略。

自体免疫诊断领域的企业行为以产品平臺开发、策略伙伴关係以及超越仪器和试剂盒本身的以服务为中心的产品组合为特征。领先的诊断试剂製造商正在投资支援多重检测和互通性的模组化平台，因为他们意识到检查室优先考虑能够整合到现有工作流程和电子健康记录中的系统。在试剂层面，供应商专注于批间一致性、易用性以及能够简化监管申报和检查室认证流程的全面验证方案。

为自体免疫诊断领域的产业领导者提供优先考虑的、可操作的建议，以加速采用、优化供应链并协调临床和商业策略。

产业领导者应优先考虑一系列切实可行的倡议，以平衡短期业务永续营运和长期策略定位。首先，应透过可视化关键组件依赖关係、保障地理分散的供应商以及协商包含应急条款的服务水准协议，来提高供应链透明度。此举有助于维持病患检测服务的连续性，同时降低贸易政策波动和物流中断带来的风险。

本文檔概述了一种高度透明的调查方法，描述了用于得出见解和确保可靠性的资料来源、专家咨询、分析框架和检验技术。

这些研究结果的基础在于对同侪审查文献、监管文件和公共指南进行系统性回顾，并结合对临床专业人员、检查室管理人员和行业高管的定向访谈。主要访谈旨在检验趋势、识别推广障碍，并了解医院、门诊和研究机构的最终用户在实际实施过程中遇到的挑战。二级资讯来源包括对诊断效能的方法学回顾、已发布的临床指南和技术评估，以确保技术准确性。

整合趋势、策略重点和可操作的后续步骤，帮助相关人员了解不断发展的自体免疫诊断生态系统。

从临床实务、技术和商业策略等整体情况来看，自体免疫诊断生态系统正日益整合。儘管诊断创新不断加深我们对疾病生物学特征和患者异质性的理解，但要实现常规临床应用，关键在于分析能力能否与临床决策、营运可行性和经济价值的显着改善相契合。能够将可靠的证据产生、切实可行的交付模式和稳健的供应链结合的相关人员，必将取得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：自体免疫疾病诊断市场：依产品划分

  • 检测试剂盒和试剂
  • 装置
    • 免疫检测分析仪
    • 微孔盘读数仪

第九章：自体免疫疾病诊断市场—检测类型

  • 自体抗体和免疫学检测
    • 抗核抗体
    • 环瓜氨酸化胜肽抗体
    • 疾病特异性自体抗体
  • 基因检测
    • 染色体检测
    • 分子检测
  • 影像检查
    • 磁振造影
    • 正子断层扫描
    • 超音波检查
  • 发炎标记物
    • C反应蛋白
    • 红血球沉积速率

第十章：自体免疫疾病诊断市场：依技术划分

  • 酵素免疫分析法
  • 流式细胞技术
  • 萤光
  • 多重侦测
  • 次世代定序
  • 蛋白质印迹法

第十一章自体免疫疾病诊断市场（依检体类型划分）

  • 血
  • 唾液
  • 尿

第十二章：自体免疫疾病诊断市场：依适应症划分

  • 器官特异性自体免疫疾病的诊断
    • 葛瑞夫兹氏病
    • 桥本氏甲状腺炎
    • 多发性硬化症
    • 1型糖尿病
  • 系统性自体免疫疾病的诊断
    • 类风湿性关节炎
    • 全身性红斑性狼疮
    • 系统性硬皮症

第十三章：自体免疫疾病诊断市场：依通路划分

  • 线下销售
  • 线上销售

第十四章：自体免疫疾病诊断市场：依最终用户划分

  • 门诊部
  • 诊断检查室
  • 医院和诊所
  • 研究机构

第十五章：自体免疫疾病诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：自体免疫疾病诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：自体免疫疾病诊断市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国自体免疫疾病诊断市场

第十九章：中国自体免疫疾病诊断市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Beckman Coulter, Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Labcorp Holdings Inc.
  • Quest Diagnostics, Inc.
  • Revvity, Inc.
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market was valued at USD 6.23 billion in 2025 and is projected to grow to USD 6.68 billion in 2026, with a CAGR of 7.45%, reaching USD 10.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.23 billion
Estimated Year [2026] USD 6.68 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 7.45%

A concise orientation to the autoimmune diagnostics landscape that frames clinical complexity technological progress and strategic imperatives for stakeholders

The autoimmune diagnostics landscape is at an inflection point driven by converging clinical demands, advances in analytical methods, and an expanded emphasis on earlier and more precise disease detection. Clinicians are asking for assays and platforms that not only confirm autoimmune activity but also stratify disease phenotype, predict progression, and inform personalized therapeutic selection. At the same time, laboratory directors and health system strategists are balancing operational efficiency with the need for higher throughput, multiplexing capabilities, and integrated data outputs that feed into electronic health records and clinical decision support tools.

Technological progress has broadened the options available to diagnosticians: classical serology methods remain foundational, while next-generation sequencing and multiplex immunoassays are enabling broader, deeper interrogation of immune signatures. These capabilities are emerging alongside growing expectations from payers and regulators for evidence of clinical utility, reproducibility, and cost-effectiveness. Consequently, manufacturers and service providers find themselves navigating a more complex value proposition that must align technical performance with demonstrable clinical impact and pragmatic implementation in diverse care settings.

Taken together, this environment demands that stakeholders-ranging from instrument vendors to hospital laboratory managers-rethink adoption pathways, reagent and instrument procurement, and clinical education. Transitional strategies that prioritize interoperability, standardized reporting, and cross-disciplinary collaboration will define who successfully translates diagnostic innovation into measurable improvements in patient care and operational outcomes

How rapid technological convergence data-driven diagnostics shifting care pathways and evolving payer dynamics are collectively redefining autoimmune disease detection and management

The transformative shifts reshaping autoimmune diagnostics reflect an intersection of technological innovation, data-centric clinical workflows, and shifting care delivery models. First, the maturation of molecular and multiplex platforms has increased the granularity of diagnostic outputs, enabling simultaneous measurement of multiple autoantibodies, inflammatory markers, or gene-level signatures. This capability is altering traditional stepwise testing algorithms by compressing timelines and reducing the need for serial assays, which in turn impacts laboratory throughput and reagent demand.

Second, the growing integration of laboratory data with digital health platforms and clinical decision support is elevating the clinical value proposition of diagnostics. Automated result interpretation, pattern recognition across combined serologic and molecular data, and the integration of imaging findings are creating more actionable diagnostic narratives for clinicians. These developments are supported by artificial intelligence and machine learning efforts that mine complex datasets to suggest diagnostic probabilities and guide subsequent testing or referral decisions.

Third, economic and regulatory pressures are prompting a shift toward demonstrable clinical utility and streamlined reimbursement pathways. Payers are increasingly asking for evidence linking specific diagnostic outputs to altered patient management or demonstrable improvements in health outcomes, which compels both manufacturers and clinical laboratories to generate robust real-world evidence and validate clinical decision thresholds.

Finally, supply chain resilience and flexible distribution have become strategic priorities. Manufacturers are adapting production footprints and forging regional partnerships to mitigate disruptions while laboratories are reevaluating outsourcing, on-site testing, and point-of-care strategies. Collectively, these shifts are not incremental; they are reorganizing how autoimmune disease is detected, characterized, and managed across the continuum of care

Assessing the cumulative impact of United States tariff policy changes in 2025 on supply chains device sourcing clinical testing workflows and industry margins

Changes to tariff policy and trade dynamics in the United States in 2025 have layered additional considerations onto an already complex diagnostic ecosystem, with effects that ripple from component sourcing to laboratory operations and procurement decisions. Manufacturers that rely on cross-border supply chains for critical reagents, assay components, or instrument subsystems may encounter increased landed costs and elongated lead times, prompting reassessment of supplier relationships and inventory strategies.

Laboratories and health systems that procure instruments and assay kits face potential rebalancing of total cost of ownership calculations. Where tariff-related cost pressures arise, purchasers may defer upgrades, extend maintenance cycles, or favor instrument-agnostic reagents and locally supplied consumables to preserve budget flexibility. In some cases, tariff signals accelerate pre-existing trends toward regionalization of manufacturing and the development of localized distribution partnerships that aim to reduce reliance on long-distance logistics.

Beyond direct procurement effects, tariffs can influence strategic behavior. Diagnostic developers may prioritize modular designs that can be assembled from regionally sourced subcomponents, thereby minimizing exposure to changing duty regimes. Contract manufacturers and suppliers positioned in tariff-favored jurisdictions become more attractive partners, and companies may evaluate the merits of relocating certain production activities to align with prevailing trade policy. At the same time, clinical laboratories are evaluating contingency plans such as diversified reagent sourcing, longer safety stock, and stronger service-level agreements with vendors to avoid disruptions to patient care.

The net consequence of these dynamics is less a single outcome and more a shift in strategic priorities: cost resilience, supply chain transparency, and flexibility in procurement become as important as analytical performance when choosing diagnostic solutions. Institutions that proactively calibrate procurement strategies and maintain open lines of communication with vendors are better positioned to manage tariff-related volatility while sustaining diagnostic capacity

Deep segmentation-led insights translating product test type technology sample type indication distribution channel and end-user breakdowns into practical strategic guidance

A segmentation-driven lens clarifies where diagnostic innovation and adoption intersect with clinical need and operational realities. Product-level distinctions between assay kits and reagents versus instruments are central to procurement decisions; laboratories may favor open-system reagents that permit cross-platform flexibility while centralized facilities invest in instruments that enable high-throughput testing and automation. The diversity of test types underscores multiple clinical pathways: autoantibodies and immunologic tests, genetic testing, imaging tests, and inflammatory marker assays each serve distinct diagnostic roles. Within autoantibodies and immunologic testing, standard panels such as antinuclear antibodies, cyclic citrullinated peptide antibodies, and disease-specific autoantibodies remain foundational for many diagnoses, whereas genetic testing spans chromosomal and molecular approaches that are increasingly leveraged for disease confirmation and risk stratification. Imaging modalities including magnetic resonance imaging, PET/CT, and ultrasound continue to provide complementary structural and functional information, while inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate offer rapid, broadly available insights into disease activity.

Technological segmentation highlights both legacy and emergent platforms. Enzyme-linked immunosorbent assays remain workhorses for single-analyte testing, while flow cytometry and immunofluorescence assays provide cellular and pattern-based data that are essential for some autoimmune workups. Multiplex assays enable more efficient profiling across panels of analytes, and next-generation sequencing introduces genomic depth that supports precision medicine approaches. Western blotting retains a niche role for confirmatory testing in select indications. Sample type considerations factor heavily into test choice and logistics; blood is the predominant matrix for most immunologic and genetic assays, while saliva and urine offer less invasive sampling that can support decentralized testing strategies and patient-centric collection workflows.

Indication-driven segmentation clarifies market priorities and clinical evidence needs. Organ-specific diagnostics, covering conditions such as Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, and type 1 diabetes, often require targeted autoantibody panels or molecular tests that support early diagnosis and monitoring. Systemic autoimmune disease diagnostics, including rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, demand integrated approaches that combine serology, imaging, and markers of inflammation to capture heterogenous disease manifestations. Distribution channels shape access and commercial strategy: offline sales remain important for institutional procurement and service contracts, whereas online sales are increasingly relevant for reagent resupply, remote test ordering, and direct-to-consumer models. Finally, end-user segmentation-from ambulatory care centers to diagnostic laboratories, hospitals and clinics, and research institutions-defines implementation pathways and informs product design choices such as throughput, automation, and ease of interpretation. By mapping clinical needs to these layered segments, stakeholders can prioritize where to invest in validation studies, commercialization efforts, and clinician education to maximize impact

Regional dynamics shaping diagnostic adoption across the Americas Europe Middle East and Africa and Asia-Pacific with implications for commercialization and clinical collaboration

Regional dynamics substantially influence the pace and shape of diagnostic adoption, regulatory approaches, and commercial strategies. In the Americas, clinical networks and centralized laboratories are major drivers of adoption for high-throughput platforms and comprehensive serologic panels, while a strong emphasis on evidence generation and payer negotiations shapes reimbursement strategies. This region often leads in integrated laboratory-clinic initiatives that pair diagnostic innovation with care pathway redesign, which can accelerate uptake when supported by local clinical champions and health economic data.

In Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and healthcare infrastructure creates a mosaic of opportunities and constraints. Western European markets tend toward early adoption of advanced platforms where regulatory harmonization and established laboratory networks permit scale. Meanwhile, markets in the Middle East and Africa may prioritize point-of-care solutions, cost-effective reagent options, and regional partnerships that address distribution challenges. Cross-border collaboration, joint ventures, and regional manufacturing hubs are common strategies to navigate logistics and regulatory variability in these territories.

Asia-Pacific presents a multiplicity of innovation vectors and rapid capacity expansion. Several markets in this region combine high-volume testing demand with significant investment in local manufacturing and digital health integration. Regulatory pathways in some Asia-Pacific jurisdictions are evolving to accommodate novel diagnostics, and public-private partnerships often support the scaling of new technologies. At the same time, country-level variation means that vendors and laboratories must craft nuanced market entry strategies, balancing centralized laboratory deployment with decentralized and point-of-care testing models to reach diverse patient populations. Across all regions, collaborative evidence generation, responsive distribution networks, and tailored reimbursement approaches remain essential to convert technical capability into sustainable clinical use

Competitive and collaboration dynamics among diagnostic manufacturers reagent suppliers instrument vendors and service providers shaping innovation pipelines and go-to-market strategies

Company behavior in autoimmune diagnostics is defined by a combination of product pipeline development, strategic partnerships, and service-centric offerings that extend beyond the instrument or kit itself. Leading diagnostic manufacturers are investing in modular platforms that support multiplexing and interoperability, recognizing that laboratories prioritize systems that integrate into existing workflows and electronic health records. At the reagent level, suppliers emphasize lot-to-lot consistency, ease of use, and comprehensive validation packages that simplify regulatory submissions and lab accreditation processes.

Collaborative models are increasingly common: firms partner with academic centers and clinical networks to generate real-world evidence that substantiates clinical utility, while technology companies collaborate with software and AI vendors to enhance result interpretation and reporting. Contract manufacturing organizations and regional suppliers play a pivotal role in augmenting manufacturing capacity and enabling faster market access in key geographies. Additionally, service providers that combine diagnostic offerings with training, quality control programs, and maintenance contracts differentiate themselves by lowering adoption friction for clinical laboratories.

Competitive dynamics also favor companies that can demonstrate coherent regulatory strategies and payer engagement. Organizations that offer bundled solutions-combining instruments, validated reagent sets, and data analytics-tend to strengthen customer retention. Simultaneously, an expanding cohort of smaller innovators brings niche assays and novel analytic approaches to market; their success often depends on strategic alliances with established distribution partners or clinical champions who can sponsor validation studies. Ultimately, companies that align technical innovation with robust evidence generation, operational support, and flexible commercial terms will capture the most durable partnerships with health systems and laboratories

Practical prioritized recommendations for industry leaders to accelerate adoption optimize supply chains and align clinical and commercial strategies in autoimmune diagnostics

Industry leaders should prioritize a set of pragmatic actions that balance near-term operational resilience with longer-term strategic positioning. First, strengthen supply chain transparency by mapping critical component dependencies, diversifying suppliers across geographies, and negotiating service-level agreements that include contingency provisions. This approach reduces exposure to trade policy shifts and logistical disruptions while maintaining continuity of patient testing services.

Second, invest in evidence generation that ties diagnostic outputs to clinical decision-making and outcomes. Collaborative real-world studies, registry linkages, and pragmatic clinical trials create the evidence payers and providers seek to justify adoption and reimbursement. Aligning these studies with clinician workflows and outcome measures relevant to therapeutic decision-making will improve the utility and uptake of novel assays.

Third, design product portfolios with interoperability and modularity in mind. Instruments and assays that accommodate both high-throughput centralized testing and decentralized point-of-care workflows increase market reach and adaptability to diverse end-user needs. Complementing hardware with cloud-enabled analytics and standardized reporting formats facilitates integration into clinical systems and supports consistent interpretation across settings.

Fourth, refine commercialization strategies to reflect regional nuance. Tailor pricing, value messaging, and service models for distinct territories, emphasizing cost-effectiveness and implementation support in markets with constrained resources while highlighting innovation and data integration in more advanced healthcare systems. Finally, cultivate strategic partnerships spanning academic centers, digital health firms, and distribution networks to accelerate validation, amplify clinical credibility, and shorten time-to-adoption. By sequencing these priorities-starting with supply chain resilience and evidence generation-organizations can create defensible market positions and translate diagnostic innovation into measurable clinical impact

Transparent research methodology outlining data sources expert consultations analytical frameworks and validation approaches used to derive insights and ensure robustness

The research underpinning these insights combined a structured review of peer-reviewed literature, regulatory documents, and public guidance with targeted interviews of clinical experts, laboratory directors, and industry executives. Primary interviews were conducted to validate trends, clarify adoption barriers, and surface practical implementation challenges experienced by end users across hospital, ambulatory, and research settings. Secondary sources included methodological reviews of diagnostic performance, published clinical guidelines, and technology assessments to ensure technical accuracy.

Analytical frameworks focused on mapping clinical pathways to diagnostic modalities and evaluating adoption drivers across product, technology, sample type, indication, distribution, and end-user segments. Regional analysis incorporated regulatory landscapes, reimbursement environments, and distribution infrastructures to identify differentiated adoption scenarios. Validation steps included cross-referencing interview findings with published cohort studies and technical evaluations to ensure coherence between reported clinical needs and the capabilities of prevailing diagnostic technologies.

Limitations were addressed by triangulating multiple data sources and clarifying areas where evidence remains emergent, such as the long-term clinical impact of certain molecular signatures and the operational implications of AI-enabled interpretation tools. Where gaps exist, recommendations emphasize pragmatic pilots and hypothesis-driven evidence generation to reduce uncertainty. Overall, this mixed-methods approach balances depth of clinical insight with the breadth needed to inform strategic decision-making for stakeholders across the diagnostic ecosystem

Synthesis of diagnostic trends strategic priorities and pragmatic next steps for stakeholders seeking to navigate the evolving autoimmune diagnostics ecosystem

The collective narrative across clinical practice, technology, and commercial strategy points to an increasingly integrated autoimmune diagnostics ecosystem. Diagnostic innovation is expanding what is knowable about disease biology and patient heterogeneity, yet the path to routine clinical use depends on aligning analytical performance with demonstrable improvements in clinical decision-making, operational feasibility, and economic value. Stakeholders that succeed will be those who combine robust evidence generation with practical delivery models and resilient supply chains.

Clinicians and laboratory leaders will need to collaborate closely to define testing algorithms that make efficient use of multiplex and molecular capabilities while reserving specialized assays for cases where incremental information changes treatment. Vendors and service providers must supply not only validated reagents and reliable instruments but also implementation support, training, and integrated data solutions that simplify interpretation and reporting. Payers and policymakers will continue to shape the environment through reimbursement policies and expectations for clinical utility, underscoring the importance of targeted evidence that addresses real-world outcomes.

In sum, the opportunities for improving diagnosis, monitoring, and personalized care in autoimmune disease are tangible, but they require coordinated action across technology providers, clinical adopters, and commercial stakeholders. Embracing interoperable platforms, prioritizing evidence generation, and executing adaptable supply chain strategies will be central to translating technological promise into sustained clinical impact

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Diagnostics Market, by Product

  • 8.1. Assay Kits & Reagents
  • 8.2. Instruments
    • 8.2.1. Immunoassay Analyzers
    • 8.2.2. Microplate Readers

9. Autoimmune Disease Diagnostics Market, by Test Type

  • 9.1. Autoantibodies & Immunologic Test
    • 9.1.1. Antinuclear Antibodies
    • 9.1.2. Cyclic Citrullinated Peptide Antibodies
    • 9.1.3. Disease-Specific Autoantibodies
  • 9.2. Genetic Testing
    • 9.2.1. Chromosomal Tests
    • 9.2.2. Molecular Tests
  • 9.3. Imaging Tests
    • 9.3.1. Magnetic Resonance Imaging
    • 9.3.2. Positron Emission Tomography
    • 9.3.3. Ultrasound
  • 9.4. Inflammatory Markers
    • 9.4.1. C-reactive protein
    • 9.4.2. Erythrocyte Sedimentation Rate

10. Autoimmune Disease Diagnostics Market, by Technology

  • 10.1. Enzyme-Linked Immunosorbent Assay
  • 10.2. Flow Cytometry
  • 10.3. Immunofluorescence Assay
  • 10.4. Multiplex Assays
  • 10.5. Next-Generation Sequencing
  • 10.6. Western Blotting

11. Autoimmune Disease Diagnostics Market, by Sample Type

  • 11.1. Blood
  • 11.2. Saliva
  • 11.3. Urine

12. Autoimmune Disease Diagnostics Market, by Indication

  • 12.1. Organ-Specific Autoimmune Disease Diagnostics
    • 12.1.1. Graves' Disease
    • 12.1.2. Hashimoto's Thyroiditis
    • 12.1.3. Multiple Sclerosis
    • 12.1.4. Type 1 Diabetes
  • 12.2. Systemic Autoimmune Disease Diagnostics
    • 12.2.1. Rheumatoid Arthritis
    • 12.2.2. Systemic Lupus Erythematosus
    • 12.2.3. Systemic Sclerosis

13. Autoimmune Disease Diagnostics Market, by Distribution Channel

  • 13.1. Offline Sales
  • 13.2. Online Sales

14. Autoimmune Disease Diagnostics Market, by End User

  • 14.1. Ambulatory Care Centers
  • 14.2. Diagnostic Laboratories
  • 14.3. Hospitals & Clinics
  • 14.4. Research Institutions

15. Autoimmune Disease Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Autoimmune Disease Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Autoimmune Disease Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Autoimmune Disease Diagnostics Market

19. China Autoimmune Disease Diagnostics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. Beckman Coulter, Inc. by Danaher Corporation
  • 20.8. Becton, Dickinson and Company
  • 20.9. Bio-Rad Laboratories, Inc.
  • 20.10. bioMerieux SA
  • 20.11. DiaSorin S.p.A.
  • 20.12. F. Hoffmann-La Roche Ltd.
  • 20.13. Grifols, S.A
  • 20.14. Labcorp Holdings Inc.
  • 20.15. Quest Diagnostics, Inc.
  • 20.16. Revvity, Inc.
  • 20.17. Siemens Healthineers AG
  • 20.18. Takeda Pharmaceutical Company Limited
  • 20.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MICROPLATE READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MICROPLATE READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MICROPLATE READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ANTINUCLEAR ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ANTINUCLEAR ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ANTINUCLEAR ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CYCLIC CITRULLINATED PEPTIDE ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CYCLIC CITRULLINATED PEPTIDE ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CYCLIC CITRULLINATED PEPTIDE ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE-SPECIFIC AUTOANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE-SPECIFIC AUTOANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE-SPECIFIC AUTOANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CHROMOSOMAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CHROMOSOMAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CHROMOSOMAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY C-REACTIVE PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY C-REACTIVE PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOTTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY OFFLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY OFFLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 281. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)

TA